Previous Close | 0.1112 |
Open | 0.1101 |
Bid | 0.1045 x 2200 |
Ask | 0.1046 x 800 |
Day's Range | 0.1026 - 0.1083 |
52 Week Range | 0.1000 - 1.9500 |
Volume | |
Avg. Volume | 3,650,506 |
Market Cap | 3.151M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EMERYVILLE, Calif., March 26, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
EMERYVILLE, Calif., March 25, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
EMERYVILLE, Calif., March 14, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor® skincare business including all product inventory for approximately $1.0 million in cash. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days.